Ignite Creation Date:
2024-05-05 @ 10:05 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00008164
Status:
UNKNOWN
Last Update Posted:
2013-12-18
First Post:
2001-01-06
Brief Title:
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Sponsor:
Herbert Irving Comprehensive Cancer Center
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Transplantation Using Umbilical Cord And Placental Blood
Status:
UNKNOWN
Status Verified Date:
2007-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells
PURPOSE Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia
PURPOSE Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia
Detailed Description:
OBJECTIVES
Determine the response rate of patients with chronic myeloid leukemia acute leukemia lymphoma myeloma myelodysplasia aplastic anemia Fanconis anemia histiocytosis hereditary immunodeficiency or storage disorder treated with allogeneic umbilical cord and placental blood transplantation
Determine the toxicity of this regimen in these patients
Determine survival in these patients treated with this regimen
Determine the incidence of graft-versus-host disease in these patients treated with this regimen
OUTLINE Patients receive a standard preparative regimen for their disease Following the preparative regimen patients undergo umbilical cord blood stem cell transplantation on day 0
Patients are followed every 1-2 weeks for 6 months
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study within 4-5 years
Determine the response rate of patients with chronic myeloid leukemia acute leukemia lymphoma myeloma myelodysplasia aplastic anemia Fanconis anemia histiocytosis hereditary immunodeficiency or storage disorder treated with allogeneic umbilical cord and placental blood transplantation
Determine the toxicity of this regimen in these patients
Determine survival in these patients treated with this regimen
Determine the incidence of graft-versus-host disease in these patients treated with this regimen
OUTLINE Patients receive a standard preparative regimen for their disease Following the preparative regimen patients undergo umbilical cord blood stem cell transplantation on day 0
Patients are followed every 1-2 weeks for 6 months
PROJECTED ACCRUAL A total of 30 patients will be accrued for this study within 4-5 years
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G00-1899 | None | None | None |
| CPMC-IRB-7934 | None | None | None |
| CPMC-CAMP-021 | None | None | None |